# OnCo record junshi (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/junshi/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "junshi" ;
  schema:name "Shanghai Junshi Biosciences"@en ;
  schema:alternateName "Junshi"@en, "君实生物"@en ;
  schema:description "Junshi developed toripalimab, the first Chinese PD-1 antibody approved in China (2018) and the first approved by the FDA (2023, nasopharyngeal cancer)."@en ;
  schema:url <https://onco.cc/companies/junshi/>, <https://www.junshipharma.com/en/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.junshipharma.com/en/>, <https://investors.coherus.com/news-releases> ;
  onco:tag "china" ;
  schema:addressCountry "CN" ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:drugs <https://onco.cc/drugs/toripalimab/>, <https://onco.cc/drugs/js105/>, <https://onco.cc/drugs/fluzoparib/>, <https://onco.cc/drugs/js111/> ;
  onco:trials <https://onco.cc/trials/jupiter-02/>, <https://onco.cc/trials/jupiter-06/>, <https://onco.cc/trials/nct06679985/> .